ABUS 8-K: SEC filing

Filed with the SEC on Nov 12, 2026 · accession 0001171843-26-007378

ABUS filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Arbutus Biopharma Corporation posted an updated corporate presentation on its website on November 12, 2026, and filed a copy as Exhibit 99.1 in a Form 8-K under Item 8.01 (Other Events).

For details, click here →How to read a 8-K →

Key details

RegistrantArbutus Biopharma Corporation

Chief financial officerTuan Nguyen

✦ Ask GOAX AI about this filing — what it means for ABUS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ABUS?

Click here

Frequently asked questions

What did ABUS file with the SEC on Nov 12, 2026?

ABUS filed a 8-K (SEC filing). Arbutus Biopharma Corporation posted an updated corporate presentation on its website on November 12, 2026, and filed a copy as Exhibit 99.1 in a Form 8-K under Item 8.01 (Other Events).

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other ABUS SEC filings

Get alerts when ABUS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

ABUS overview ABUS analysis ABUS news Latest SEC filings